Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics.
about
The Potential for Microalgae as Bioreactors to Produce PharmaceuticalsRecombinant pharmaceuticals from microbial cells: a 2015 updateEcology of cold environments: new insights of bacterial metabolic adaptation through an integrated genomic-phenomic approachEnabling Low Cost Biopharmaceuticals: A Systematic Approach to Delete Proteases from a Well-Known Protein Production Host Trichoderma reesei.Integration and Validation of the Genome-Scale Metabolic Models of Pichia pastoris: A Comprehensive Update of Protein Glycosylation Pathways, Lipid and Energy MetabolismComparative genomics and transcriptomics of Pichia pastoris.Modelling microbial metabolic rewiring during growth in a complex mediumDynamic genome-scale metabolic modeling of the yeast Pichia pastorisAdaptive laboratory evolution -- principles and applications for biotechnology.Engineering protein self-assembling in protein-based nanomedicines for drug delivery and gene therapy.Photosynthetic biomanufacturing in green algae; production of recombinant proteins for industrial, nutritional, and medical uses.Recombinant protein materials for bioengineering and nanomedicine.Engineering the supply chain for protein production/secretion in yeasts and mammalian cells.Functional protein aggregates: just the tip of the iceberg.Structural and functional features of self-assembling protein nanoparticles produced in endotoxin-free Escherichia coli.Comprehensive clone screening and evaluation of fed-batch strategies in a microbioreactor and lab scale stirred tank bioreactor system: application on Pichia pastoris producing Rhizopus oryzae lipaseA novel synthetic medium and expression system for subzero growth and recombinant protein production in Pseudoalteromonas haloplanktis TAC125.CXCR4(+)-targeted protein nanoparticles produced in the food-grade bacterium Lactococcus lactis.Production, secretion and purification of a correctly folded staphylococcal antigen in Lactococcus lactis.Production of Recombinant Trichoderma reesei Cellobiohydrolase II in a New Expression System Based on Wickerhamomyces anomalus.Quantitative Metabolomics and Instationary 13C-Metabolic Flux Analysis Reveals Impact of Recombinant Protein Production on Trehalose and Energy Metabolism in Pichia pastorisComparison of intracellular and secretion-based strategies for production of human α-galactosidase A in the filamentous fungus Trichoderma reesei.Pichia pastoris secretes recombinant proteins less efficiently than Chinese hamster ovary cells but allows higher space-time yields for less complex proteinsImproving recombinant protein production in the Chlamydomonas reinhardtii chloroplast using vivid Verde Fluorescent Protein as a reporterImproved performance of protein-based recombinant gene therapy vehicles by tuning downstream procedures.Systems metabolic engineering, industrial biotechnology and microbial cell factories.Bacterial cell factories for recombinant protein production; expanding the catalogueExpanding the recombinant protein quality in Lactococcus lactis.Genome-scale metabolic reconstruction and constraint-based modelling of the Antarctic bacterium Pseudoalteromonas haloplanktis TAC125.Fine-tuning the P. pastoris iMT1026 genome-scale metabolic model for improved prediction of growth on methanol or glycerol as sole carbon sources.Microbial biofabrication for nanomedicine: biomaterials, nanoparticles and beyond.An improved secretion signal enhances the secretion of model proteins from Pichia pastorisGenome-scale phylogenetic and DNA composition analyses of Antarctic Pseudoalteromonas bacteria reveal inconsistencies in current taxonomic affiliationTargeting low-density lipoprotein receptors with protein-only nanoparticlesBiomedical Applications of Bacterial Inclusion Bodies
P2860
Q26744351-D9EADE94-79B8-4433-8171-2C032F8BF4BFQ28074222-7B4242BA-377C-44EF-A1D3-D0BE4190269FQ33678319-3D2D834D-26E3-4A9A-BA96-1CBFEE1EC24DQ35756279-5950414A-76DE-4FB9-B264-C071EDE450C1Q35905001-CE6F5030-1E97-4D2A-AE1F-DAE135732B1FQ36096375-0822F9AB-0ABF-452A-B2DE-26D486981A00Q36202760-0689460C-9D99-4AFA-812C-44FFD870EF2DQ36286865-9DFD7EAE-30C3-4261-8737-CC4B69F83601Q38118393-FAE0B9A5-A374-4595-B299-7E4599F36192Q38150365-CB3B9E49-7492-4708-BD13-BE5011170CEDQ38198558-F9731A36-C8F2-407F-8E88-9822E41C6F50Q38298810-735FF436-64ED-4783-98ED-9877722AEB06Q38308441-D07AE6B2-FA02-4756-A42E-45ECD265EF32Q38586804-FE142780-040F-4A05-9EF4-EF852DBD745AQ38779740-1E1F38DA-0D0A-49B9-B5E1-5306F6E3B00AQ39149049-D561CDFA-C692-4193-A6FD-D69320356D50Q39234015-C3292662-13F0-47E2-8FF6-AA01B6DB80EDQ39485838-BD8EB403-638B-42E5-99C0-BFF447CA909BQ40732946-E6BF7334-8C94-48BD-AF4A-55D35DD98565Q41688501-188FF400-D321-4FE7-A2E8-7B9FD96B60BCQ41808560-6CC16F45-148E-4C6C-942C-0C91BB1472BCQ41854355-D81C74AE-797A-4251-8E58-8AC3F981C10AQ41986845-4259541C-F303-4D1E-AADB-B00B70027EF4Q42025528-55AE551C-FB5B-4E1B-86F4-3D23B39203CEQ42275850-8A9040CE-D863-4714-A75B-CBE091D8ABBBQ42575388-31BCD098-C47A-4F0D-8E1B-64927F48B160Q42862786-B0AA017A-D596-4B56-93BA-D1BE7D20192EQ43121684-7A280BB9-4D7A-487A-A9A3-A7715B5C90BCQ46890072-0A3F24EA-1F42-4B4A-99DD-07485D12B767Q47146888-346899C8-6A84-45E1-B9DD-725D4A836CEDQ54532341-7D852DDF-8450-4169-ABCE-44D82D42C676Q57471845-1FE1915B-5DC0-4B48-9F75-7A7BAFE8465AQ57672746-852D585B-1F1A-4C52-8846-0FA2C220834FQ59201788-20EC3AB6-091E-4D74-ABE1-91B812B4C204Q59201792-81E72623-AE58-406C-AB59-48CA1EC9515F
P2860
Unconventional microbial systems for the cost-efficient production of high-quality protein therapeutics.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Unconventional microbial syste ...... -quality protein therapeutics.
@en
type
label
Unconventional microbial syste ...... -quality protein therapeutics.
@en
prefLabel
Unconventional microbial syste ...... -quality protein therapeutics.
@en
P2093
P50
P1476
Unconventional microbial syste ...... h-quality protein therapeutics
@en
P2093
David Resina
Felícitas Vázquez
Jussi Jäntti
Maria Giuliani
Markku Saloheimo
Wesley Smith
P304
P356
10.1016/J.BIOTECHADV.2012.09.001
P50
P577
2012-09-15T00:00:00Z